Therapy Areas: Oncology
Antengene enters into clinical trial collaboration with BeiGene
27 June 2022 -

Antengene Corporation Limited, a China-based commercial-stage global biopharmaceutical company involved in discovering, developing and commercialising first-in-class and/or best-in-class therapeutics in haematology and oncology, announced on Sunday that it has entered into a clinical trial collaboration with BeiGene, a China-based global, science-driven biotechnology company.

The collaboration is aimed at assessing the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizumab. This multi-centre, open-label Phase I/II trial is intended to assess the investigational combination as a potential treatment option for patients with T and NK-cell lymphoma.

Tislelizumab is a PD-1 inhibitor aimed at supporting the body's immune cells to detect and fight tumours. Selinexor is an orally-available, selective inhibitor of the nuclear export protein XPO1.



Related Headlines